{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:38:08Z","timestamp":1771472288084,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K19242"],"award-info":[{"award-number":["JP20K19242"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with Parkinson\u2019s disease often experience sleep disorders. Hypnotics increase the risk of adverse events, such as injuries due to falls. In this study, we evaluated the association between hypnotics and injuries among older adults with Parkinson\u2019s disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study used a nested case\u2013control design. The participants were 5009 patients with Parkinson\u2019s disease aged\u2009\u2265\u200975 years based on claims data between April 2016 and March 2019 without prescription hypnotics 1 year before the study started. Hypnotics prescribed as oral medications included benzodiazepines, non-benzodiazepines, orexin receptor antagonists, and melatonin receptor agonists. The incidences of outcomes, including injuries, fractures, and femoral fractures, were determined. Each case had four matched controls. Conditional logistic regression analyses were performed to calculate the odds ratios and 95% confidence intervals for the number of hypnotics taken per day for each type of hypnotic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The proportion of participants taking at least one type of hypnotic was 18.6%, with benzodiazepines being the most common. The incidence of injuries, fractures, and femoral fractures was 66.7%, 37.8%, and 10.2%, respectively. Benzodiazepines significantly increased the risk of injuries (odds ratio: 1.12; 95% confidence interval: 1.03\u20131.22), and melatonin receptor agonists significantly increased the risk of femoral fractures (odds ratio: 2.84; 95% confidence interval: 1.19\u20136.77).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Benzodiazepines and non-benzodiazepines, which are not recommended according to current guidelines, were the most prevalent among older adults with Parkinson\u2019s disease. Benzodiazepines significantly increased the risk of injuries, and melatonin receptor agonists significantly increased the risk of femoral fractures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-023-03944-9","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T12:02:24Z","timestamp":1682942544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypnotics and injuries among older adults with Parkinson\u2019s disease: a nested case\u2013control design"],"prefix":"10.1186","volume":"23","author":[{"given":"Takako","family":"Fujita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Babazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-a","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"11","key":"3944_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey. ER, Nichols EA, E, Abbasi. N, Abd-Allah F, Abdelalim A. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353.","journal-title":"Lancet Neurol"},{"issue":"3","key":"3944_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/ageing\/afj087","volume":"35","author":"V Dhawan","year":"2006","unstructured":"Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson\u2019s disease. Age Ageing. 2006;35(3):220\u20138.","journal-title":"Age Ageing"},{"issue":"6","key":"3944_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/WCO.0000000000000388","volume":"29","author":"P Bargiotas","year":"2016","unstructured":"Bargiotas P, Schuepbach MW, Bassetti CL. Sleep-wake disturbances in the premotor and early stage of Parkinson\u2019s disease. Curr Opin Neurol. 2016;29(6):763\u201372.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"3944_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00415-020-10140-x","volume":"268","author":"Z Xu","year":"2021","unstructured":"Xu Z, Anderson KN, Saffari SE, Lawson RA, Chaudhuri KR, Brooks D, et al. Progression of sleep disturbances in Parkinson\u2019s disease: a 5-year longitudinal study. J Neurol. 2021;268(1):312\u201320.","journal-title":"J Neurol"},{"key":"3944_CR5","volume-title":"Clinical practice guideline for Parkinson\u2019s disease in Japan 2018","author":"Japanese Society of Neurology","year":"2018","unstructured":"Japanese Society of Neurology. Clinical practice guideline for Parkinson\u2019s disease in Japan 2018. Tokyo: Igakushoin; 2018."},{"issue":"8","key":"3944_CR6","doi-asserted-by":"publisher","first-page":"e0161246","DOI":"10.1371\/journal.pone.0161246","volume":"11","author":"Y Haasum","year":"2016","unstructured":"Haasum Y, Fastbom J, Johnell K. Use of fall-risk inducing drugs in patients using Anti-Parkinson drugs (APD): a Swedish Register-Based study. PLoS ONE. 2016;11(8):e0161246.","journal-title":"PLoS ONE"},{"issue":"4","key":"3944_CR7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"2019 American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"key":"3944_CR8","volume-title":"Guidelines for medical treatment and its safety in the elderly 2015","author":"The Japan Geriatrics Society","year":"2015","unstructured":"The Japan Geriatrics Society. Guidelines for medical treatment and its safety in the elderly 2015. Tokyo: Medical View; 2015."},{"issue":"2","key":"3944_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"issue":"9836","key":"3944_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012;380(9836):37\u201343.","journal-title":"The Lancet"},{"key":"3944_CR11","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.5888\/pcd16.180170","volume":"16","author":"S Mitsutake","year":"2019","unstructured":"Mitsutake S, Ishizaki T, Teramoto C, Shimizu S, Ito H. Patterns of co-occurrence of chronic disease among older adults in Tokyo, Japan. Prev Chronic Dis. 2019;16:E11.","journal-title":"Prev Chronic Dis"},{"issue":"1","key":"3944_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-017-0904-4","volume":"17","author":"G McLean","year":"2017","unstructured":"McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson\u2019s disease: insights from a large scottish primary care database. BMC Neurol. 2017;17(1):126.","journal-title":"BMC Neurol"},{"key":"3944_CR13","doi-asserted-by":"crossref","unstructured":"Benzinger P, Rapp K, Maetzler W, Koenig H-H, Jaensch A, Klenk J et al. Risk for Femoral Fractures in Parkinson\u2019s Disease Patients with and without Severe Functional Impairment.Plos One. 2014;9(5).","DOI":"10.1371\/journal.pone.0097073"},{"issue":"8","key":"3944_CR14","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00198-013-2300-2","volume":"24","author":"S Pouwels","year":"2013","unstructured":"Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, et al. Risk of fracture in patients with Parkinson\u2019s disease. Osteoporos Int. 2013;24(8):2283\u201390.","journal-title":"Osteoporos Int"},{"issue":"8","key":"3944_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1248\/yakushi.20-00018","volume":"140","author":"T Ishigo","year":"2020","unstructured":"Ishigo T, Takada R, Kondo F, Ibe Y, Nakano K, Tateishi R, et al. Association suvorexant and ramelteon use with the risk of falling: a retrospective case-control study. Yakugaku Zasshi. 2020;140(8):1041\u20139.","journal-title":"Yakugaku Zasshi"},{"issue":"6","key":"3944_CR16","doi-asserted-by":"publisher","first-page":"e0129366","DOI":"10.1371\/journal.pone.0129366","volume":"10","author":"H Tamiya","year":"2015","unstructured":"Tamiya H, Yasunaga H, Matusi H, Fushimi K, Ogawa S, Akishita M. Hypnotics and the occurrence of bone fractures in hospitalized dementia patients: a matched case-control study using a national inpatient database. PLoS ONE. 2015;10(6):e0129366.","journal-title":"PLoS ONE"},{"issue":"6","key":"3944_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/jcpt.13619","volume":"47","author":"R Sogawa","year":"2022","unstructured":"Sogawa R, Emoto A, Monji A, Miyamoto Y, Yukawa M, Murakawa-Hirachi T, et al. Association of orexin receptor antagonists with falls during hospitalization. J Clin Pharm Ther. 2022;47(6):809\u201313.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"3944_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41386-019-0448-y","volume":"45","author":"A Stefani","year":"2020","unstructured":"Stefani A, Hogl B. Sleep in Parkinson\u2019s disease. Neuropsychopharmacology. 2020;45(1):121\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"3944_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2169\/internalmedicine.55.5464","volume":"55","author":"K Kashihara","year":"2016","unstructured":"Kashihara K, Nomura T, Maeda T, Tsuboi Y, Mishima T, Takigawa H, et al. Beneficial effects of ramelteon on rapid eye movement sleep behavior disorder associated with Parkinson\u2019s disease - results of a multicenter open trial. Intern Med. 2016;55(3):231\u20136.","journal-title":"Intern Med"},{"issue":"7","key":"3944_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","volume":"25","author":"WJ Herring","year":"2017","unstructured":"Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, et al. Suvorexant in Elderly patients with Insomnia: pooled analyses of data from Phase III randomized controlled clinical trials. Am J Geriatr Psychiatry. 2017;25(7):791\u2013802.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"3944_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/02698811211069096","volume":"36","author":"SJ Davies","year":"2022","unstructured":"Davies SJ, Rudoler D, de Oliveira C, Huang A, Kurdyak P, Iaboni A. Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: a population-based cohort study. J Psychopharmacol. 2022;36(4):460\u20139.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"3944_CR22","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/mds.23168","volume":"25","author":"M Menza","year":"2010","unstructured":"Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, et al. Treatment of insomnia in Parkinson\u2019s disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708\u201314.","journal-title":"Mov Disord"},{"issue":"1","key":"3944_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12890-016-0359-1","volume":"17","author":"T Ishifuji","year":"2017","unstructured":"Ishifuji T, Sando E, Kaneko N, Suzuki M, Kilgore PE, Ariyoshi K, et al. Recurrent pneumonia among japanese adults: disease burden and risk factors. BMC Pulm Med. 2017;17(1):12.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3944_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/gps.4310","volume":"31","author":"T Maeda","year":"2016","unstructured":"Maeda T, Babazono A, Nishi T, Yasui M. Quantification of adverse effects of regular use of triazolam on clinical outcomes for older people with insomnia: a retrospective cohort study. Int J Geriatr Psych. 2016;31(2):186\u201394.","journal-title":"Int J Geriatr Psych"},{"issue":"10","key":"3944_CR25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/jnnp-2013-307307","volume":"85","author":"KM Torsney","year":"2014","unstructured":"Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ. Bone health in Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85(10):1159\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"3944_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jbspin.2016.09.022","volume":"84","author":"M Laroche","year":"2017","unstructured":"Laroche M, Pecourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, et al. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84(4):427\u201332.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"3944_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice Guideline for Diabetes 2019. Diabetol Int. 2020;11(3):165\u2013223.","journal-title":"Diabetol Int"},{"issue":"3","key":"3944_CR28","doi-asserted-by":"publisher","first-page":"300060521999555","DOI":"10.1177\/0300060521999555","volume":"49","author":"L Zhang","year":"2021","unstructured":"Zhang L, Liu Q, Zeng X, Gao W, Niu Y, Ma X, et al. Association of dyslipidaemia with osteoporosis in postmenopausal women. J Int Med Res. 2021;49(3):300060521999555.","journal-title":"J Int Med Res"},{"issue":"12","key":"3944_CR29","doi-asserted-by":"publisher","first-page":"e14999","DOI":"10.1111\/ijcp.14999","volume":"75","author":"WF Ong","year":"2021","unstructured":"Ong WF, Kamaruzzaman SB, Tan MP. Falls in older persons with type 2 diabetes in the malaysian Elders Longitudinal Research (MELoR) study. Int J Clin Pract. 2021;75(12):e14999.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"3944_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-020-05619-2","volume":"29","author":"S Sattar","year":"2021","unstructured":"Sattar S, Haase K, Kuster S, Puts M, Spoelstra S, Bradley C, et al. Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment. Support Care Cancer. 2021;29(1):21\u201333.","journal-title":"Support Care Cancer"},{"issue":"3","key":"3944_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16(3):541\u201351.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"3944_CR32","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-020-05535-5","volume":"31","author":"C Tanislav","year":"2020","unstructured":"Tanislav C, Kostev K. Factors associated with fracture after stroke and TIA: a long-term follow-up. Osteoporos Int. 2020;31(12):2395\u2013402.","journal-title":"Osteoporos Int"},{"issue":"2","key":"3944_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jpr.12287","volume":"63","author":"C Osawa","year":"2020","unstructured":"Osawa C, Kamei Y, Nozaki K, Furusawa Y, Murata M. Brief cognitive behavioral therapy for insomnia in Parkinson\u2019s disease: a case series study. Japan Psychol Res. 2020;63(2):59\u201371.","journal-title":"Japan Psychol Res"},{"key":"3944_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-017-0027-z","volume":"3","author":"M Humbert","year":"2017","unstructured":"Humbert M, Findley J, Hernandez-Con M, Chahine LM. Cognitive behavioral therapy for insomnia in Parkinson\u2019s disease: a case series. NPJ Parkinsons Dis. 2017;3:25.","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"3944_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/jclp.22883","volume":"76","author":"C Lebrun","year":"2020","unstructured":"Lebrun C, Gely-Nargeot MC, Rossignol A, Geny C, Bayard S. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson\u2019s disease: a focus on psychological and daytime functioning with a single-case design with multiple baselines. J Clin Psychol. 2020;76(3):356\u201376.","journal-title":"J Clin Psychol"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-03944-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-023-03944-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-03944-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T12:03:58Z","timestamp":1682942638000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-023-03944-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3944"],"URL":"https:\/\/doi.org\/10.1186\/s12877-023-03944-9","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Kyushu University (Clinical Bioethics Committee of the Graduate School of Healthcare Sciences, Kyushu University), permission number 2021\u2009\u2212\u2009335. The study was conducted in accordance with the Ethical Guidelines for Medical and Biological Research involving Human Subjects in Japan. As we used anonymized claims insurance data, informed consent was waived by the Institutional Review Board of Kyushu University (Clinical Bioethics Committee of the Graduate School of Healthcare Sciences, Kyushu University), permission number 2021\u2009\u2212\u2009335.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}